In attempting to qualify for clinical trial for subject scan at JH , I was informed that another trial (ORIOLE) was in process , led by Dr. Tran , to use the subject scan to determine if only a few mets (oligometastatic) were present which could be treated with SBRT , obviating the need for " onerous" HT. I assume (maybe incorrectly) that SBRT would only be used if mets were in
locations not previously radiated.
Any thoughts on use of SBRT for stage pt3b gl9 PCa particularly after I've had so many previous IMRT treatments ( see signature)?
DOB January 1944 (now age 73)
PSA: 8/12 2.7; 5/13, 6.6 (actually double due to finasteride)
7/13 (age 69) Bx GS 4+4=8 (Bostwick); GS 4+5=9 (Epstein); 2 of 6 cores, 10%, 40%; stage Pt1c
8/13 bone scan negative
9/13 ORRP at John Hopkins, GS 4+5=9, BLSVIs+, margin+ (4mm,G7), EPE, 10 Nodes resected (clear); stage upgraded to pt3bN0M0
PSA: 11/13 0.1; 2/14 0.2; 5/14 0.3
6/14 SRT by IMRT/IGRT, Lewis cancer Ctr. 68.2 grays/38 sessions to prostate bed, ADT (6 months Lupron)
PSA: 9/14 to 8/15: <.1, <.1, .1, .3, .7, 1.2
7/15 CT-PET f-18 bone scan negative
9/15 MRI, CT-PET at Sand Lake Imaging find iliac lymph nodes suspicious for PCa; organs and soft tissue clear
9/15-12/15 IMRT/D.A.R.T. at Dattoli , 75 grays/50 sessions to all pelvic lymph nodes
9/15-11/16: 13 months ADT3 (Lupron, bicaludimide, dutasteride) plus Metformin, Cabergoline, Estradiol patch, Prolia , Vitamin D3, calcium
6/16: color-flow Doppler ultrasound, combined helical CT pelvis, abdomen and chest and QCT for bone density and FDG 18 Pet scan negative for PCa
12/16: color-flow Doppler ultrasound, combined helical CT pelvis, abdomen and chest and QCT for bone density negative for PCa; finasteride added to dutasteride.
PSA: 11/15 .084; 3/16 .034; 6/16 .028; 9/16 .045; 12/16 .194; 1/17 .484
Post Edited (Break60) : 2/15/2017 7:11:11 AM (GMT-7)